ijms-logo

Journal Browser

Journal Browser

From Basic Science to Treatment Strategies: Personalized Cancer Therapy, 2nd Edition

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Pathology, Diagnostics, and Therapeutics".

Deadline for manuscript submissions: closed (31 October 2024) | Viewed by 529

Special Issue Editor


E-Mail Website
Guest Editor
Department of Hematology & Oncology, Memorial Health Care System, Memorial Cancer Institute, Hollywood, FL 33021, USA
Interests: targeted therapy; personalized medicine; immunotherapy; circulating tumor DNA; prognosis; genomic profiling; liquid biopsies
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

As Volume 1 of the Special Issue “From Basic Science to Treatment Strategies: Personalized Cancer Therapy” was successful, we reopen this Special Issue again in the International Journal of Molecular Sciences (ISSN 1422-0067, IF 5.6, JCR Category Q1).

For this Special Issue, we will continue to highlight the recent advances in cancer care in which targeting patient-specific genomic and pathway abnormalities has become the standard of care for the vast majority of cancer patients. For example, we will highlight advances in targeting isocitrate dehydriogenase, fibroblast growth factor receptor, human epidermal growth factor receptor 2, B-raf protooncogene/mitogne-activated protein kinase (BRAF/MEK), claudin, hypoxia-inducible factor, folate-receptor alpha, epidermal growth factor receptor, ROS protooncogene 1 (ROS1), neurotrophic tropomyosin kinase receptor (NTRK), met protooncogene, and others. We will also highlight the use of liquid biopsies to diagnose some of those abnormalities. The use of circulating DNA in cancer patients is being used more and more to determine who needs systemic therapy and for prognostic information.

Dr. Atif Hussein
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • targeted therapy
  • personalized medicine
  • immunotherapy
  • circulating tumor DNA
  • prognosis
  • genomic profiling
  • liquid biopsies

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

18 pages, 295 KiB  
Review
Oncogenic Fusions in NSCLC: From Mechanisms to Clinical Applications
by Nyein Wint Yee Theik, Suset Almuinas De Armas, Daniel Rosas, Amy Kiamos, Nyein Nyein Thaw Dar, Ahmed Shoreibah, Atif Hussein and Luis E. Raez
Int. J. Mol. Sci. 2025, 26(8), 3802; https://doi.org/10.3390/ijms26083802 - 17 Apr 2025
Viewed by 251
Abstract
Non-small cell lung cancer (NSCLC) is operated commonly by diverse genetic alterations, and oncogenic fusions represent a significant therapeutic role. Common fusions include ALK, ROS1, RET, and NTRK, signaling pathways in tumorigenesis. Recent advances in investigating tumor molecular biology include underlying fusions, including [...] Read more.
Non-small cell lung cancer (NSCLC) is operated commonly by diverse genetic alterations, and oncogenic fusions represent a significant therapeutic role. Common fusions include ALK, ROS1, RET, and NTRK, signaling pathways in tumorigenesis. Recent advances in investigating tumor molecular biology include underlying fusions, including chromosomal rearrangements, highlighting their role as oncogenic drivers. The development of targeted therapies, such as tyrosine kinase inhibitors (TKIs), has impacted most patients’ NSCLC treatment. Despite the greater profiles, such as remarkable efficiency and tolerable side effects compared to traditional chemotherapy, challenges, such as acquired mutations, lead to more ongoing research-optimized future NSCLC therapies. Full article
Back to TopTop